A ROR1 targeted bispecific T cell engager shows high potency in the pre-clinical model of triple negative breast cancer
Collectively, these results demonstrated that ROR1/CD3 TCE has a promising efficacy profile in preclinical studies, which suggested it as a possible option for the treatment of ROR1-expressing TNBC.
Authors
- Jun Xie (ORCID: https://orcid.org/0000-0001-9340-2997)
- Fan Wang (ORCID: https://orcid.org/0000-0002-9869-9504)
- Xiangdong Bai (ORCID: https://orcid.org/0000-0002-0980-2515)
- Guohui Han
- Weina Li (ORCID: https://orcid.org/0009-0000-9463-8790)
Institutions
- Shanxi Medical University (CN)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-03-31
- DOI
- https://doi.org/10.1186/s13058-025-02005-w
- Citations
- 5
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 5.23